Progenics Signs an Exclusive Agreement with ROTOP Pharmaka to Develop and Commercialize Imaging Agent 1404 for Prostate Cancer in Europe

Progenics Signs an Exclusive Agreement with ROTOP Pharmaka to Develop and Commercialize Imaging Agent 1404 for Prostate Cancer in Europe

Shots:

  • Progenics to receive royalties on sales of 1404 in EU. ROTOP to get an exclusive license to develop & commercialize 1404 in EU and is also responsible for regulatory approvals
  • The focus of the agreement is to expand ROTOP’s PSMA targeted prostate cancer portfolio and to accelerate the development of 1404 for treating prostate cancer in Europe
  • Progenic’s 1404 is a prostate specific membrane antigen (PSMA) targeting SPECT/CT imaging agent labeled with technetium-99m, designed for the detection of primary and metastatic prostate cancer with its expected clinical trials onset in H1’20

Click here to read full press release/ article | Ref: Progenics | Image: Annual Reports